Lv3
270 积分 2026-03-13 加入
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study
9天前
已完结
[Clinical Analysis of Autologous Hematopoietic Stem Cell Transplantation in Treatment of Mantle Cell Lymphoma: a Multicenter Retrospective Study]
9天前
已关闭
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
18天前
已完结
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
1个月前
已完结
Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after the BTK inhibitor era
1个月前
已完结
Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterations
1个月前
已完结
Quality of life in advanced‐stage, asymptomatic, non‐bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful‐waiting
2个月前
已完结
The future of follicular lymphoma management: strategies on the horizon
2个月前
已完结
皖公网安备34019202002308
